PD43: Kidney Cancer: Basic Research & Pathophysiology II

Sunday, May 15, 2022

9:30 AM – 11:30 AM

Location: Room 244

Podium Session Moderator(s)

Jodi Maranchie, MD (she/her/hers)

University of Pittsburgh
Simon Tanguay, MD

McGill University
Benjamin Lee, MD

Professor & Chair, The George W. Drach, MD Endowed Chair, Department of Urology
University of Arizona College of Medicine

Presentations:

9:30 AM – 9:40 AM

PD43-01: Pevonedistat Sensitizes Renal Medullary Carcinoma Cells to Carboplatin by Disrupting DNA Damage Repair Mechanisms
Podium Presenter: Daniel Shapiro, MD
9:40 AM – 9:50 AM

PD43-02: Therapeutic efficacy of YM155 to repress an epigenetic enzyme and everolimus resistance in RCC.
Podium Presenter: Hyun Ji Hwang – Hanyang University
9:50 AM – 10:00 AM

PD43-03: MCT inhibition synergizes with tyrosine kinase and mTOR inhibitor treatment in renal cell carcinoma
Podium Presenter: Nagalakshmi Nadiminty
10:00 AM – 10:10 AM

PD43-04: PD-L1 localization within Exosomes: A Pre-Clinical Study on Exosome Targeting Therapies to Combat Drug Resistance in Renal Cell Carcinoma
Podium Presenter: Jacob W. Greenberg, BS
10:10 AM – 10:20 AM

PD43-05: A novel siRNA-based nanotherapy against metastatic clear cell renal cell carcinoma
Podium Presenter: Jan Krzysztof Rudzinski, MD, FRCSC, MSc – Faculty of Medicine University of Calgary
10:20 AM – 10:30 AM

PD43-06: EZH2 inhibition as therapeutic strategy to dysregulate LATS1 in RCC
Podium Presenter: Seong Hwi Hong, PHD – Hanayang University
10:30 AM – 10:40 AM

PD43-07: TKI-induced treatment resistance of RCC via modulating the long non-coding RNA-ECVSR/ER&[beta]/Hif2-&[alpha] signaling
Podium Presenter: Yixi Hu
10:40 AM – 10:50 AM

PD43-08: Development of patient-derived kidney cancer organoid; Application to drug screening models and its challenges
Podium Presenter: Akira Kazama – Niigata University Graduate School of Medical and
10:50 AM – 11:00 AM

PD43-09: Phenotypical Screening onMetastatic PRCC-TFE3 FusionTranslocation Renal Cell Carcinoma Organoids RevealsPotential Therapeutic Agents
Podium Presenter: Chuanzhen Cao
11:00 AM – 11:10 AM

PD43-10: Cancer-associated adipose-derived mesenchymal stem cells promote migration and invasion in kidney cancer
Podium Presenter: Yumina Muto
11:10 AM – 11:20 AM

PD43-11: Methylation heterogeneity in ccRCC offers insights into tumorigenesis and biomarker development
Podium Presenter: Sabrina Helena Rossi, MD, MBBS
11:20 AM – 11:30 AM

PD43-12: Biomarks for kidney cancer differentiation
Podium Presenter: Barbara Köditz